Last reviewed 2026-04-20 · How we verify

Clarithromycin 500 mg

Clarithromycin 500 mg, marketed by Rehman Medical Institute (RMI), is an established antibiotic in the pharmaceutical market. The key composition patent for Clarithromycin is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the potential increase in generic competition following the patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication (NA)
• Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
• Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
• Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
• A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults (PHASE1)
• Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
• Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC (PHASE2)
• Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.